Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX).Compared to the S&P 500 index, which is down about ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

CAMBRIDGE, Mass. & SALISBURY, England, April 08, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary ...

Approximately 4,000 people living with CF in the European Union are newly eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON--(BUSINESS WIRE)--Apr. 7, ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company best known for its treatments for cystic fibrosis and other serious diseases. During a segment last year, Cramer ...

Casgevy has blockbuster potential, even considering CRISPR Therapeutics will share the spoils with Vertex Pharmaceuticals with which it developed the treatment. Further, CRISPR Therapeutics has a ...